AKT1 and pancreatic neoplasm: Liraglutide suppresses protein kinase B (Akt) phosphorylation in pancreatic cancer cells by activating GLP-1R, thus inhibiting tumor growth via suppression of the PI3K/Akt signaling pathway [63].